Company: PSTV
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0001140361-25-013256
Chunk: 30

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 30
---
 our authorized Common Stock is attached as Annex Bto this Proxy Statement. Following the increase in authorized shares as contemplated in the Certificate of Amendment to the Certificate of Incorporation (the “Certificate of Amendment”), 2,000,000,000 shares of Common Stock and 5,000,000 shares of preferred stock will be authorized. There will be no changes to the issued and outstanding shares of Common Stock or preferred stock as a result of the effectiveness of the Certificate of Amendment. Reasons for the Increase in Authorized Common Stock Contemporaneously with the Private Placement, the Board has determined that the increase in our authorized shares of Common Stock is in the best interests of the Company and unanimously recommends approval by the stockholders to allow for future issuance of the maximum shares issuable under the transaction documents of the Private Placement, which we currently estimate at approximately 1,570,359,840. In addition, the Board believes that the availability of additional authorized shares of Common Stock is required for several reasons including, but not limited to, the additional flexibility to issue Common Stock for a variety of general corporate purposes as the Board may determine to be desirable including, without limitation, future financings, investment opportunities, acquisitions, or other distributions and stock splits (including splits effected through the declaration of stock dividends). As of the Record Date, 11,785,078 shares of our Common Stock were issued and outstanding. Our working capital requirements are significant and may require us to raise additional capital through additional equity financings in the future. If we issue additional shares of Common Stock or other securities convertible into shares of our Common Stock in the future, it could dilute the voting rights of existing stockholders and could also dilute earnings per share and book value per share of existing stockholders. The increase in authorized number of Common Stock could also discourage or hinder efforts by other parties to obtain control of the Company, thereby having an anti-takeover effect. The increase in authorized number of Common Stock is not being proposed in response to any known threat to acquire control of the Company. Current Plans, Proposals or Arrangements to Issue Shares of Common Stock As of the Record Date, the Company had:

| • | 1,152,707 shares of Common Stock issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $3.94 per share; and |

| • | 8,743 shares of Common Stock reserved for future issuance under the 2020 Plan. |

The increase in the authorized shares of Common Stock is necessary to allow for